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ABSTRACT
Background Ventilator-acquired pneumonia (VAP)
remains a signiﬁcant problem within intensive care units
(ICUs). There is a growing recognition of the impact of
critical-illness-induced immunoparesis on the
pathogenesis of VAP, but the mechanisms remain
incompletely understood. We hypothesised that, because
of limitations in their routine detection,
Mycoplasmataceae are more prevalent among patients
with VAP than previously recognised, and that these
organisms potentially impair immune cell function.
Methods and setting 159 patients were recruited from
12 UK ICUs. All patients had suspected VAP and underwent
bronchoscopy and bronchoalveolar lavage (BAL). VAP was
deﬁned as growth of organisms at >104 colony forming
units per ml of BAL ﬂuid on conventional culture. Samples
were tested for Mycoplasmataceae (Mycoplasma and
Ureaplasma spp.) by PCR, and positive samples underwent
sequencing for speciation. 36 healthy donors underwent
BAL for comparison. Additionally, healthy donor monocytes
and macrophages were exposed to Mycoplasma salivarium
and their ability to respond to lipopolysaccharide and
undertake phagocytosis was assessed.
Results Mycoplasmataceae were found in 49% (95% CI
33% to 65%) of patients with VAP, compared with 14%
(95% CI 9% to 25%) of patients without VAP. Patients
with sterile BAL ﬂuid had a similar prevalence to healthy
donor BAL ﬂuid (10% (95% CI 4% to 20%) vs 8% (95%
CI 2% to 22%)). The most common organism identiﬁed
was M. salivarium. Blood monocytes from healthy
volunteers incubated with M. salivarium displayed an
impaired TNF-α response to lipopolysaccharide (p=0.0003),
as did monocyte-derived macrophages (MDMs) (p=0.024).
MDM exposed to M. salivarium demonstrated impaired
phagocytosis (p=0.005).
Discussion and conclusions This study demonstrates
a high prevalence of Mycoplasmataceae among patients
with VAP, with a markedly lower prevalence among patients
with suspected VAP in whom subsequent cultures refuted
the diagnosis. The most common organism found, M.
salivarium, is able to alter the functions of key immune
cells. Mycoplasmataceae may contribute to VAP
pathogenesis.
INTRODUCTION
Ventilator-acquired pneumonia (VAP) remains a sig-
niﬁcant cause of morbidity and mortality in
patients admitted to the intensive care unit (ICU).1
There is a growing recognition of failure of
immune cell function (immunoparesis) in the lung2
and peripherally3 4 in the pathogenesis of VAP. The
mediators of this immunoparesis remain incom-
pletely understood, although it is likely that it
arises from multifactorial insults involving both
host and microbial factors. It is now widely recog-
nised that the predominant route for infection is
via ‘microaspiration’ of organisms from the hypo-
pharynx, allowing colonisation and subsequent
infection of the lower airways.1
The organisms which cause VAP have tradition-
ally been thought to be conventional bacterial
species, such as Staphylococcus aureus and
Pseudomonas aeruginosa.5 However our under-
standing of the microbiology of VAP is heavily
inﬂuenced by the relative ease of microbial culture.
In recent years there has been a greater understand-
ing of the human microbiome and the inﬂuence of
bacteria that are not cultured.6 Recent reports have
suggested that non-classical organisms, such as
Mycoplasma spp., may be present in patients with
VAP.7 8 The methods of detection used in these
studies have been variable and there was little evi-
dence of the impact these species may have on host
immunity.
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Key messages
What is the key question?
▸ What is the prevalence of Mycoplasmataceae
among patients with ventilator-acquired
pneumonia (VAP), and does this have any
pathophysiological relevance?
What is the bottom line?
▸ Patients with VAP have a high prevalence of
Mycoplasmataceae compared with similar
patients without VAP, and the most common
species found can impair immune cell function.
Why read on?
▸ These ﬁndings provide a novel insight into the
biology of VAP and suggest new potential
prevention strategies.
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Mycoplasmataceae are members of the mollicutes class of bac-
teria, which lack a cell wall and have the smallest genomes found
in self-replicating organisms.9 Their limited biosynthetic capabil-
ity makes culture and detection problematic, needing specialised
growth media and prolonged incubation or reliance on indirect
methods such as serology.9 A range of Mycoplasmataceae such as
Mycoplasma salivarium and M. orale are generally considered to
be human commensals,10 while others such as M. pneumoniae
and Ureaplasma urealyticum are recognised pathogens of the
respiratory and genitourinary tract, respectively. However, even
the Mycoplasma spp. commonly thought to be commensals have
been shown to cause infections in immunocompromised hosts.11
Additionally, co-infection with Mycoplasma spp. has been impli-
cated in accelerated progression of HIV/AIDS.12
We hypothesised that patients with conﬁrmed VAP would
have a higher prevalence of Mycoplasmataceae than patients
without VAP, and that the dominant organism found (M. salivar-
ium) would impair the ability of monocytes and macrophages to
respond to further bacterial stimuli. Accordingly, this study had
two aims; ﬁrst, to quantify the prevalence of Mycoplasmataceae
in two cohorts of patients with suspected VAP and determine
which species were present. The second aim was to examine the
effect of a classically non-pathogenic Mycoplasma, M. salivar-
ium, on the ability of monocytes and macrophages to respond
to pathogenic stimuli.
METHODS
Patients and volunteers
We constructed the subject cohorts for this study from clinical
samples and data from two recent patient studies and a healthy
volunteer cohort.13 14 The ﬁrst patient cohort was recruited
from two general, teaching hospital ICUs from 2005 to 2009.
Patients were included if they fulﬁlled clinical criteria for sus-
pected VAP, that is, mechanical ventilation for >48 h, new inﬁl-
trates on chest radiograph, and at least two of the following:
temperature >38°C, leucocyte count >11×109 per litre of per-
ipheral blood or purulent tracheal secretions.
The second patient cohort was recruited from 12 ICUs across
the UK from 2012 to 2013, and met similar enrolment criteria
to those in patient cohort 1. Both cohorts 1 and 2 underwent a
standardised bronchoscopy and bronchoalveolar lavage (BAL) as
described.13 14 In both cohorts VAP was conﬁrmed by growth
of organisms at >104 colony forming units per ml of BAL ﬂuid
(CFU/mL) on conventional culture.
The healthy volunteers were recruited from the University of
Edinburgh and from a primary care practice. Volunteers under-
went either bronchoscopy and BAL using the same protocol as
used in patient cohort 1, or phlebotomy for extraction of per-
ipheral blood leucocytes for the leucocyte function experiments
detailed below.
Sample processing
BAL ﬂuid was prepared as described,13 with the cell-free super-
natant being stored at −80°C. Aliquots of BAL ﬂuid from
patient cohort 1 and healthy volunteers underwent nucleic acid
extraction by one of the authors (NJG) using the DNeasy Blood
and Tissue kit (Qiagen, Manchester, UK) with pretreatment
protocol for Gram-positive bacteria, according to the manufac-
turer’s instructions. Extractions for patient cohort 2 were under-
taken by another author ( JPM) using the MagNA pure 96 DNA
and viral NA small volume kit (Roche, Indianapolis, Indiana,
USA) in a geographically separate laboratory. The extraction in
two laboratories was undertaken to conﬁrm that the
Mycoplasma detection was not occurring due to contamination
of consumables in one or other laboratory. Further conﬁrmation
came by running the PCR on saline passed through the same
extraction columns but without contact with the patient or vol-
unteer BAL ﬂuid samples.
PCR for Mycoplasma spp. was based on the method of van
Kuppeveld et al15 targeting the 16S rRNA gene using forward
primer general prokaryotic oligonucleotides-1 (GPO-1) and
reverse primer mycoplasma genus-speciﬁc oligonucleotides
(MGSO) and gel electrophoresis for detection. Positive extracts
were sequenced on the reverse strand to determine Mycoplasma
spp. using the QIAquick PCR puriﬁcation kit (Qiagen) for puri-
ﬁcation, and ABI Prism BigDye Terminator and the ABI 3730
instrument (Applied Biosystems, Life Technologies, Paisley, UK)
for Sanger sequencing. Ureaplasma spp. real-time PCR was
based on an inhouse unpublished method targeting the urease
gene using the following oligonucleotides; UreF: ACG WCG
TTT CGA TAT TCC AT, UreR: TTC CRT TAA CTA AGC CRT
TT and UreP: 60FAM—TCG TTT TGA ACC AGG AGA YAA
AA—BHQ1. Reactions comprised HotStarTaq (Qiagen)
reagents, 0.5 μM primer Ure-F, 0.65 μM primer UreR, 0.2 μM
probe UreP and 10 μL nucleic acid extract to a ﬁnal volume of
25 μL. Real-time PCR was carried out on the ABI 7500 instru-
ment (Applied Biosystems). Ureaplasma spp. positive extracts
were speciated using the method of Kong et al16 targeting the 50
end of the MBA gene with primers UMS-57c and UMA222 for
U. parvum and UMS-170c and UMA263 for U. urealyticum,
followed by gel-based detection.
Human inﬂammatory cell/Mycoplasma interactions
Human mononuclear cells were obtained from whole blood
from healthy donors using previously described methods.17 18
Brieﬂy, leucocytes were obtained by dextran sedimentation, with
separation of mononuclear and granulocytic cells over Percoll
gradients. CD14+ve monocytes were extracted from the mono-
nuclear fraction using a magnetic bead system (MACS, Miltenyi
Biotec, Bisley, UK), and >95% purity conﬁrmed by ﬂow cyto-
metry. Monocytes were either used fresh at 300 000 per well,
or matured into monocyte-derived macrophages (MDMs).
MDMs were produced by adhering 300 000 monocytes to
24-well tissue culture plates (Corning Costar, Sigma-Aldrich,
Gillingham, UK) and incubating in Iscove’s modiﬁed Dulbecco’s
medium and 10% autologous serum for 7 days. MDM matur-
ation was conﬁrmed morphologically using light microscopy.
Exposure to Mycoplasma
Monocytes and MDMs were initially exposed to three titres of
live M. salivarium strain NC10113 (Mycoplasma Experience,
Bletchingley, UK), namely multiplicity of infection (MOI) of
1:10 (low), 1:1 (moderate) and 10:1 (high) for 24 h at 37°C
and 5% CO2. Cell death was assessed by nuclear staining using
Sytox Green (Life Technologies) and ﬂuorescence microscopy,
counting the number of ﬂuorescent cells in three randomly
selected ﬁelds per well, with a minimum of 100 cells per ﬁeld.
All experiments were conducted in duplicate using a minimum
of n=3 individual donors.
Inﬂuence of Mycoplasma on response to lipopolysaccharide
Monocytes and MDMs were cultured as above and exposed to
either live M. salivarium or vehicle control for 24 h.
Supernatants were removed, centrifuged at 200 g for 10 min
and frozen for later analysis. In subsequent experiments mono-
cytes and MDMs were cultured with M. salivarium or vehicle
control for 24 h and then, without washing or changing super-
natant, exposed to lipopolysaccharide (Escherichia coli 0127:B8,
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Sigma-Aldrich, Gillingham, UK) at 100 ng/mL for a further
24 h, before supernatants were removed and processed as
above. Cytokines were assayed using Cytometric Bead Array
(BD Biosciences, Oxford, UK).
Effect of Mycoplasma on phagocytosis by MDMs
MDMs were exposed to live M. salivarium or vehicle control
for either short (60 min) or long (24 h) incubations. Following
this the cells were presented with a phagocytic target, pHrodo
Red Zymosan (Life Technologies) that had been opsonised in
autologous donor serum. Cells were exposed to 0.02 mg/mL
zymosan for 30 min before being placed on ice and phagocyt-
osis assessed by ﬂuorescence microscopy.
Statistical analysis
Categorical variables were expressed as proportions and com-
pared using Fisher’s exact test. Continuous variables were
expressed as mean values and compared using one-way analysis
of variance (ANOVA) with Bonferroni’s post hoc test for com-
parison between individual conditions. All analyses were per-
formed using Prism (Graphpad Software, La Jolla, California,
USA). p≤0.05 was considered statistically signiﬁcant.
Ethical approval
The samples from patient cohorts 1 and 2 were collected in
studies approved by the Lothian Research Ethics Committee
(REC) (LREC/2002/8/19) and NRES North East REC (11/NE/
0242) and Scotland A REC (11/SS/0089), respectively, with the
informed consent/assent from the next of kin. The healthy volun-
teer BAL ﬂuid was obtained from volunteers in a study approved
by Lothian REC (06/S1101/50) with all volunteers giving written
informed consent. The monocyte and MDM experiments were
conducted using cells obtained under the authorisation of the
Lothian REC (08/S1103/38) following written, informed
consent.
RESULTS
Settings and patients
In total there were 159 patients (67 from cohort 1, 92 from
cohort 2) for analysis, of whom 43 (13 from cohort 1 and 30
from cohort 2) had conﬁrmed VAP. The demographics of
patient cohorts 1 and 2 have been described previously;13 14
brieﬂy the patients were 69% male, with a median age of
60 years (IQR 48–71), 45% were admitted to ICU with surgical
diagnoses with the remainder admitted with medical diagnoses.
Median APACHE II score was 20 (IQR 16–24), ICU mortality
was 28% and hospital mortality 35%. Further demographic
details are shown in the online supplementary table S1.
Thirty-six healthy donors underwent BAL using the same proto-
col as cohort 1.13
Detection of Mycoplasma and Ureaplasma spp.
Detection of Mycoplasmataceae (Mycoplasma and Ureaplasma
spp.) occurred signiﬁcantly more frequently in patients with
VAP compared with those without VAP (table 1). This was the
case for both patient cohorts. Among patients without VAP, the
frequency of Mycoplasmataceae was higher in those who had
some growth on culture as opposed to those whose BAL ﬂuid
was sterile by conventional culture, although none of these dif-
ferences reached statistical signiﬁcance (table 1). The frequency
of Mycoplasmataceae detection did not differ signiﬁcantly
between patients with sterile cultures and healthy volunteers
(p=1.0 by Fisher’s exact test, ﬁgure 1), nor was the trend in dif-
ference between all non-VAP patients and healthy volunteers sig-
niﬁcant (14% (95% CI 9% to 25%) vs 8% (95% CI 2% to
22%), p=0.57 by Fisher’s exact test).
The majority (82%) of Mycoplasmataceae detected in patients
were Mycoplasma spp., and within this group M. salivarium
Figure 1 Proportion of healthy volunteers and patients with no
microbial growth (by conventional culture) in whom Mycoplasmataceae
were detected. Data shown as proportion and upper 95% CI. p Value
by Fisher’s exact test.
Table 1 Frequency of Mycoplasmataceae detection in patients with and without VAP confirmed by conventional microbiological culture
Non-VAP subdivision
Cohort VAP (>104 CFU/mL) Non-VAP (<104 CFU/mL or sterile)
Sub-104 CFU/mL
growth Sterile
1 7/13
54% (25–81%)
10/54
19% (9–31%)
(p=0.014)
6/23
26% (10–48%)
4/31
13% (4–31%)
(p=0.29)
2 14/30
47% (28–66%)
6/62
10% (4–20%)
(p=0.0001)
3/26
12% (2–30%)
3/36
8% (2–22%)
(p=0.69)
Combined cohorts 21/43
49% (33–65%)
16/116
14% (9–25%)
(p<0.0001)
9/49
18% (9–32%)
7/67
10% (4–20%)
(p=0.28)
The non-VAP subdivision is of patients with growth below the 104 CFU/mL cut-off and those with no detectable growth. Data are shown as raw values, percentage (95% CI by
Clopper–Pearson method), p values by Fisher’s exact test for comparison between VAP and non-VAP groups (column 3) and for comparison between sub-104 CFU/mL growth and sterile
(column 5).
CFU, colony forming unit; VAP, ventilator-acquired pneumonia.
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was the dominant organism detected (table 2). Two healthy
volunteers were positive for Mycoplasma spp. by PCR but
sequencing revealed non-Mycoplasmataceae organisms
(Solobacterium moorei) and these samples were excluded from
the ‘positive’ samples. Among the remaining three healthy vol-
unteer samples that were positive for Mycoplasma spp. sequen-
cing revealed one M. salivarium and two mixed species.
The presence of atypical organisms did not differ signiﬁcantly
between patients with VAP arising from differing aetiological
classes (table 3).
Effect of M. salivarium coculture on monocyte and MDM
function
Following the discovery of a high prevalence of M. salivarium
among patients with VAP (52% of Mycoplasmataceae in patients
with VAP were M. salivarium), we hypothesised that this species
may have a role to play in the pathogenesis of VAP. We therefore
examined the effect of M. salivarium infection on the ability of
key immune cells, monocytes and macrophages, to respond to
bacterial stimuli.
M. salivarium and cellular toxicity
Neither monocytes nor MDMs exposed to live M. salivarium for
24 h at MOIs of 1:10 (low) and 1:1 (moderate) exhibited signiﬁ-
cantly greater cell death than untreated cells (ﬁgure 2A, B). A
high MOI (10:1) induced 30% cell death in MDMs (ﬁgure 2B,
far right column). Monocytes appeared relatively resistant to
such effects (ﬁgure 2A), although demonstrated an overall higher
basal level of cellular death than MDMs. Subsequent experi-
ments were conﬁned to low and moderate exposures for both
cell types.
M. salivarium selectively impairs the ability of immune cells
to respond to stimulation with lipopolysaccharide
As expected, lipopolysaccharide (LPS) alone signiﬁcantly
increased the secretion of tumour necrosis factor (TNF)-α,
interleukin (IL) 6 and IL-10 from monocytes and MDM (ﬁgure
3); in general M. salivarium alone had a similar but smaller
effect (see online supplementary tables S3 and S4). However,
the TNF-α response to an LPS challenge was impaired following
both low and moderate M. salivarium exposure in monocytes
and macrophages (p=0.0003 and p=0.0024 by ANOVA, respect-
ively) (ﬁgure 3A, B). A similar although slightly less pronounced
pattern was seen with IL-6 (p=0.0006 and p=0.04) and IL-10
(p=0.02 and p=0.004) secretion (ﬁgure 3C–F). IL-8 secretion
showed a contrasting pattern, being unchanged in monocytes
(p=0.55) while macrophages showed enhanced IL-8 secretion
withMycoplasma exposure (p=0.0013) (ﬁgure 3G, H).
M. salivarium impairs phagocytosis by macrophages
Phagocytosis of microbes and other particulate matter by macro-
phages is a key part of pulmonary defences, as it directs destruc-
tion of the microorganism and facilitates antigen presentation to
effector cells19 M. salivarium signiﬁcantly impaired phagocytosis
by macrophages following 24 h exposure (ﬁgure 4), with
Table 2 Species of atypical organism detected in patients (two
patients had both Mycoplasma spp. and Ureaplasma spp. detected)
Organism n/frequency
Mycoplasma hominis 2 (5%)
Mycoplasma salivarium 22 (56%)
Ureaplasma parvum 1 (3%)
Ureaplasma urealyticum 4 (10%)
Mixed species of Mycoplasma, unable to further speciate 8 (21%)
Unable to speciate (Ureaplasma sp +ve by PCR) 2 (5%)
Table 3 Mycoplasmataceae detection among patients with VAP
(ie, growth at >104CFU/mL) of various aetiologies
VAP pathogen N=
Proportion positive for atypical organisms, %
(n)
Gram-positive bacteria 12 58 (7)
Gram-negative
bacteria
20 35 (7)
Fungi and yeasts 7 57 (4)
Mixed organism types 4 75 (3)
p=0.41 by χ2. Details of species grown are shown in online supplementary table S2.
CFU, colony forming unit; VAP, ventilator-acquired pneumonia.
Figure 2 Cell death associated with Mycoplasma salivarium in
monocytes and monocyte-derived macrophages (MDMs). (A). Numbers
of Sytox green positive monocytes as a proportion of total cells from
three randomly selected ﬁelds per condition, n=3 individual donors.
p=0.56 by ANOVA. Data shown as mean and SD. (B). Numbers of
Sytox green positive MDMs as a proportion of total cells from three
randomly selected ﬁelds per condition, n=3 individual donors.
p<0.0001 by ANOVA, ****p<0.0001 by Bonferroni’s post hoc test, all
other comparisons non-signiﬁcant by Bonferroni’s test. Data shown as
mean and SD.
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moderate titre having a more pronounced effect than low titre
(p=0.005 by ANOVA).
DISCUSSION
This study is, to our knowledge, the most comprehensive descrip-
tion of Mycoplasmataceae in VAP to date. Through the use of
molecular diagnostics we have conﬁrmed previous ﬁndings of
Mycoplasma presence7 8 in a more robust manner and, import-
antly, identiﬁed the species involved. We have also demonstrated
the presence of small numbers of Ureaplasma spp., organisms
more commonly found in genitourinary tract infections.
It is, perhaps, surprising that the dominant organism is an
oral commensal which is commonly regarded as non-
pathogenic.10 We did not ﬁnd a single classically pathogenic
Mycoplasma spp., which is in contrast to ﬁndings from authors
in other countries.7 8 However M. salivarium is found in the
oral cavity of 97% of the healthy population,10 and therefore is
available to be microaspirated past the endotracheal cuff along-
side other organisms in the oropharyngeal space.5 Although
we undertook targeted PCR rather than pan-bacterial
metagenomics, the appearance of Mycoplasmataceae may reﬂect
a change in the lung microbiome, an effect that has been noted
in other pulmonary infections.20 The role of lung microbiome
shift in the pathogenesis and maintenance of pulmonary infec-
tion is an area of active, ongoing investigation.20
The striking difference in prevalence between patients with
and without microbiologically conﬁrmed VAP invites several
possible explanations. First, the presence of Mycoplasma spp. in
BAL may simply reﬂect the burden of microaspiration from the
oropharynx. Second, the presence of Mycoplasma in BAL ﬂuid
may be indicative of a relative immune failure2 which leaves
patients unable to clear these low pathogenicity organisms, with
the immune failure being more pronounced in those who
develop VAP. A third possibility is that Mycoplasma may contrib-
ute to the pathogenesis of VAP by directly impairing immune
function, thus facilitating infection by other ‘classical’ VAP
pathogens.
Although we cannot answer these questions deﬁnitively, and
there may be contributions from all three, we undertook the
monocyte/Mycoplasma experiments to look for proof of
Figure 3 Effect of exposing
monocytes and monocyte-derived
macrophages (MDMs) to Mycoplasma
salivarium and lipopolysaccharide
(LPS), on cytokine secretion. (A) TNF-α
secretion by monocytes, p=0.0003 by
ANOVA. (B) TNF-α secretion by MDMs,
p=0.0024 by ANOVA. (C) Interleukin
(IL) 6 secretion by monocytes,
p=0.0006 by ANOVA. (D) IL-6 secretion
by MDMs, p=0.04 by ANOVA. (E) IL-10
secretion by monocytes, p=0.02 by
ANOVA. (F) IL-10 secretion by MDMs,
p=0.004 by ANOVA. (G) IL-8 secretion
by monocytes, p=0.55 by ANOVA. (H)
IL-8 secretion by MDMs, p=0.0013 by
ANOVA. *p<0.05, **p<0.01,
***p<0.001 by Bonferroni’s post-hoc
test, all other comparisons were
non-signiﬁcant by Bonferroni’s test.
Results are from duplicates of n=3
individual healthy donors, with
300 000 cells per well. Data shown as
mean and SD. MOI, multiplicity of
infection.
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principle of Mycoplasma-induced immune impairment that may
support the third hypothesis. Among patients with HIV/AIDS,
co-infection with Mycoplasma spp. is associated with faster pro-
gression of a disease which is characterised by immune failure,12
although the causative relationship remains controversial21 22
and the Mycoplasma spp. implicated are those more commonly
associated with the genitourinary tract.21 In previous in vitro
studies in human monocytic cell lines23 and bovine monocytes24
the presence of unspeciﬁed Mycoplasma spp.23 and M. bovis24
respectively have been associated with impaired immune
responses. The mechanism by which M. salivarium alters innate
immune cell function is the focus of ongoing work, however
our data do not support this being simply an effect of cellular
toxicity. Interestingly, the effects on cytokine secretion are
complex with reductions in LPS-induced secretion of TNF-α,
IL-6 and IL-10 but unaffected (monocyte) or stimulated (MDM)
IL-8 production. The standard description of ‘deactivated/repro-
grammed’ monocytes in patients with sepsis is of reduced
TNF-α and enhanced IL-10 secretion.25 Thus the effects we
have seen with Mycoplasma may reﬂect a related but different
phenomenon to classical ‘LPS tolerance’.25 Indeed Zakharova
et al found a similar Mycoplasma-mediated suppression of
IL-10 transcription in monocyte-like THP-1 cells.23 Although
we can only speculate on the potential in vivo effects, it is pos-
sible that when Mycoplasma spp. enter the already inﬂamed
lung their predominant suppressive effect is maladaptive and
promotes infection but the same effect in its ‘normal’ environ-
ment contributes to an adaptive microbiota-induced immune
tolerance.20 26
We believe this study has a number of strengths. First we
examined a large number of samples taken from the alveolar
region of the lungs of patients with suspected VAP and these
samples came from a range of locations throughout the UK. It is
therefore unlikely that these ﬁndings are speciﬁc to a single unit
or geographical region. Second, by using the latest molecular
techniques we were able (A) to identify Mycoplasma with
greater conﬁdence than previous studies which relied on
Mycoplasma toxin detection7 or limited PCR,8 and (B) to iden-
tify the speciﬁc species involved. Third, by undertaking examin-
ation of the effects of the most common identiﬁed species, M.
salivarium, on two key innate immune cells, we were able to
strengthen our hypothesis that this organism is not simply a
bystander but is contributing to the immunoparesis that facili-
tates VAP.
Our study is limited by having a sample from a single time
point, at the time of suspected infection. Therefore we cannot
comment on when the Mycoplasmataceae appeared in the
alveolar space relative to the development of VAP. As such we
are certainly unable to infer a causative relationship between
Mycoplasmataceae and subsequent VAP. Our positive event rate
of 21 patients with Mycoplasmataceae and VAP prevents more
in-depth examination of the relationship between Mycoplasma-
taceae, clinical features and outcomes from VAP. We were also
unable to precisely quantify the amounts of non-classical organ-
isms present in the lungs of patients, although the ability to
obtain good speciation data for the great majority of the
Mycoplasma positive samples from patients with VAP suggests a
reasonable bacterial load. The titres of M. salivarium to which
the monocytic cells were exposed therefore remain an approxi-
mation of the situation in vivo. Indeed our in vitro model of
Mycoplasma infection is necessarily a simpliﬁcation of the in
vivo situation.
The implications of this work are that preventing lower
respiratory tract Mycoplasma spp. infection, through improved
oral hygiene measures and prevention of microaspiration, may
contribute to preventing VAP through immune restoration. This
hypothesis could also provide a novel explanation for the
ﬁnding that incorporating macrolides to antibiotics for VAP
improves outcomes,27 beyond the more widely accepted immu-
nomodulatory effects of macrolides.28 We do not, however,
advocate broadening antibiotic coverage on the basis of our
ﬁndings, as only further clinical trials could justify such an
approach. The high prevalence of Mycoplasmataceae among
patients with VAP should also be considered when pan-bacterial
molecular diagnostics, such as 16S rRNA gene PCR, are being
used for pathogen detection in VAP; mixed sequences are difﬁ-
cult to resolve using conventional Sanger-based sequencing and
may require next-generation sequencing methodologies.
In conclusion we have found a high prevalence of non-
classical bacterial species among patients with VAP, speciﬁcally
organisms such as M. salivarium that are traditionally thought
to be non-pathogenic. We have further demonstrated that these
organisms can alter antibacterial functions in healthy volunteer
monocytes and MDMs, and may have the potential to contrib-
ute to the immunoparesis seen in critically ill patients.
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